Dysregulation of KRAS signaling in pancreatic cancer is not
associated with KRAS mutations and outcome

J 2017

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome

LEMSTROVA, Radmila; Veronika BRYNYCHOVA; David J. HUGHES; Viktor HLAVAS; Pavel DVORAK et. al.

Základní údaje

Originální název

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome

Autoři

Vydání

Oncology Letters, Athens, SPANDIDOS PUBL LTD, 2017, 1792-1074

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.664

Kód RIV

RIV/00216224:14110/17:00097981

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.3892/ol.2017.6946

UT WoS

000415083000127

EID Scopus

2-s2.0-85030163410

Klíčová slova anglicky

pancreatic ductal adenocarcinoma; KRAS; gene expression; mutation; overall survival

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 18. 3. 2018 22:38, Soňa Böhmová

Anotace

V originále

Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, and no targeted therapy is currently available. The aim of the present study was to investigate the prognostic significance of the expression of V-Ki-ras2 kirsten rat sarcoma viral oncogene homolog (KRAS), downstream signaling pathway genes and the association with clinical characteristics in PDAC patients undergoing radical surgery. Tumors and adjacent non-neoplastic pancreatic tissues were examined in 45 patients with histologically verified PDAC. KRAS and B-Raf proto-oncogene, serine/threonine kinase (BRAF) gene mutation analysis was performed using the KRAS/BRAF/phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha array.

Citovat

LEMSTROVA, Radmila; Veronika BRYNYCHOVA; David J. HUGHES; Viktor HLAVAS; Pavel DVORAK; Joanne E. DOHERTY; Helena A. MURRAY; Martin CROCKARD; martin OLIVERIUS; Jan HLAVSA; Eva HONSOVA; Jan MAZANEC; Zdeněk KALA; Martin LOVECEK; Roman HAVLIK; Jiri EHRMANN; Ondrej STROUHAL; Pavel SOUCEK; Bohuslav MELICHAR a Beatrice MOHELNIKOVA-DUCHONOVA. Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. Oncology Letters. Athens: SPANDIDOS PUBL LTD, 2017, roč. 14, č. 5, s. 5980-5988. ISSN 1792-1074. Dostupné z: https://doi.org/10.3892/ol.2017.6946.

@article{1393056,
   author = {Lemstrova, Radmila and Brynychova, Veronika and Hughes, David J. and Hlavas, Viktor and Dvorak, Pavel and Doherty, Joanne E. and Murray, Helena A. and Crockard, Martin and Oliverius, martin and Hlavsa, Jan and Honsova, Eva and Mazanec, Jan and Kala, Zdeněk and Lovecek, Martin and Havlik, Roman and Ehrmann, Jiri and Strouhal, Ondrej and Soucek, Pavel and Melichar, Bohuslav and MohelnikovaandDuchonova, Beatrice},
   article_location = {Athens},
   article_number = {5},
   doi = {https://doi.org/10.3892/ol.2017.6946},
   keywords = {pancreatic ductal adenocarcinoma; KRAS; gene expression; mutation; overall survival},
   language = {eng},
   issn = {1792-1074},
   journal = {Oncology Letters},
   title = {Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome},
   volume = {14},
   year = {2017}
}

TY  - JOUR
ID  - 1393056
AU  - Lemstrova, Radmila - Brynychova, Veronika - Hughes, David J. - Hlavas, Viktor - Dvorak, Pavel - Doherty, Joanne E. - Murray, Helena A. - Crockard, Martin - Oliverius, martin - Hlavsa, Jan - Honsova, Eva - Mazanec, Jan - Kala, Zdeněk - Lovecek, Martin - Havlik, Roman - Ehrmann, Jiri - Strouhal, Ondrej - Soucek, Pavel - Melichar, Bohuslav - Mohelnikova-Duchonova, Beatrice
PY  - 2017
TI  - Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
JF  - Oncology Letters
VL  - 14
IS  - 5
SP  - 5980-5988
EP  - 5980-5988
PB  - SPANDIDOS PUBL LTD
SN  - 17921074
KW  - pancreatic ductal adenocarcinoma
KW  - KRAS
KW  - gene expression
KW  - mutation
KW  - overall survival
N2  - Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, and no targeted therapy is currently available. The aim of the present study was to investigate the prognostic significance of the expression of V-Ki-ras2 kirsten rat sarcoma viral oncogene homolog (KRAS), downstream signaling pathway genes and the association with clinical characteristics in PDAC patients undergoing radical surgery. Tumors and adjacent non-neoplastic pancreatic tissues were examined in 45 patients with histologically verified PDAC. KRAS and B-Raf proto-oncogene, serine/threonine kinase (BRAF) gene mutation analysis was performed using the KRAS/BRAF/phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha array.
ER  -

LEMSTROVA, Radmila; Veronika BRYNYCHOVA; David J. HUGHES; Viktor HLAVAS; Pavel DVORAK; Joanne E. DOHERTY; Helena A. MURRAY; Martin CROCKARD; martin OLIVERIUS; Jan HLAVSA; Eva HONSOVA; Jan MAZANEC; Zdeněk KALA; Martin LOVECEK; Roman HAVLIK; Jiri EHRMANN; Ondrej STROUHAL; Pavel SOUCEK; Bohuslav MELICHAR a Beatrice MOHELNIKOVA-DUCHONOVA. Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. \textit{Oncology Letters}. Athens: SPANDIDOS PUBL LTD, 2017, roč.~14, č.~5, s.~5980-5988. ISSN~1792-1074. Dostupné z: https://doi.org/10.3892/ol.2017.6946.

Přehled o publikaci